Pediatric Drug Formulations: A Review of Challenges and Progress
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Children differ from adults in many aspects of pharmacotherapy, including capabilities for drug administration, medicine-related toxicity, and taste preferences. It is essential that pediatric medicines are formulated to best suit a child’s age, size, physiologic condition, and treatment requirements. To ensure adequate treatment of all children, different routes of administration, dosage forms, and strengths may be required. Many existing formulations are not suitable for children, which often leads to off-label and unlicensed use of adult medicines. New regulations, additional funding opportunities, and innovative collaborative research initiatives have resulted in some recent progress in the development of pediatric formulations. These advances include a paradigm shift toward oral solid formulations and a focus on novel preparations, including flexible, dispersible, and multiparticulate oral solid dosage forms. Such developments have enabled greater dose flexibility, easier administration, and better acceptance of drug formulations in children. However, new pediatric formulations address only a small part of all therapeutic needs in children; moreover, they are not always available. Five key issues need to be addressed to stimulate the further development of better medicines for children: (1) the continued prioritization of unmet formulation needs, particularly drug delivery in neonates and treatment gaps in pediatric cancers and childhood diseases in developing countries; (2) a better use of existing data to facilitate pediatric formulation development; (3) innovative technologies in adults that can be used to develop new pediatric formulations; (4) clinical feedback and practice-based evidence on the impact of novel formulations; and (5) improved access to new pediatric formulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and Children
Kearns, G. L., Abdel-Rahman, S. M., Alander, S. W., Blowey, D. L., Leeder, J. S., & Kauffman, R. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmra035092 · Cited by 2,421
Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications
Menjoge, A. R., Kannan, R. M., & Tomalia, D. A. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.01.009 · Cited by 795
Bartelink, I. H., Rademaker, C. M. A., Schobben, A. F. A. M., & van den Anker, J. N. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645110-00003 · Cited by 418
Self-citationFATAL BENZYL ALCOHOL POISONING IN A NEONATAL INTENSIVE CARE UNIT
Brown, W., Buist, N. M., Cory Gipson, H., Huston, R., & Kennaway, N. (1982) · The Lancet · doi:10.1016/s0140-6736(82)92377-7 · Cited by 397
Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults
Fernandez, E., Perez, R., Hernandez, A., Tejada, P., Arteta, M., & Ramos, J. T. (2011) · Pharmaceutics · doi:10.3390/pharmaceutics3010053 · Cited by 370
Editorial comment: Therapeutic orphans
Shirkey, H. (1968) · The Journal of Pediatrics · doi:10.1016/s0022-3476(68)80414-7 · Cited by 359
A literature review on off-label drug use in children
Pandolfini, C., & Bonati, M. (2005) · European Journal of Pediatrics · doi:10.1007/s00431-005-1698-8 · Cited by 346
Extrapolation of Adult Data and Other Data in Pediatric Drug-Development Programs
Dunne, J., Rodriguez, W. J., Murphy, M. D., Beasley, B. N., Burckart, G. J., Filie, J. D., Lewis, L. L., Sachs, H. C., Sheridan, P. H., Starke, P., et al. (2011) · Pediatrics · doi:10.1542/peds.2010-3487 · Cited by 318
Pediatric Exposure and Potential Toxicity of Phthalate Plasticizers
Shea, K. M., & Committee on Environmental Health (2003) · Pediatrics · doi:10.1542/peds.111.6.1467 · Cited by 310
Formulation of medicines for children
Nunn, T., & Williams, J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02410.x · Cited by 272
Paediatric and geriatric drug delivery
Breitkreutz, J., & Boos, J. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.1.37 · Cited by 262
Cuzzolin, L., Atzei, A., & Fanos, V. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.5.703 · Cited by 252
Unlicensed and Off-Label Drug Use in Children: Implications for Safety
Choonara, I., & Conroy, S. (2002) · Drug Safety · doi:10.2165/00002018-200225010-00001 · Cited by 224
Extrapolation of Adult Data and Other Data in Pediatric Drug-Development Programs
(2011) · PEDIATRICS · doi:10.1542/peds.2010-3487d · Cited by 224
Off-label Drug Use in Hospitalized Children
Shah, S. S., Hall, M., Goodman, D. M., Feuer, P., Sharma, V., Fargason, C., Hyman, D., Jenkins, K., White, M. L., Levy, F. H., et al. (2007) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.161.3.282 · Cited by 221
PATHOLOGIC EFFECTS OF ELIXIR OF SULFANILAMIDE (DIETHYLENE GLYCOL) POISONING
Geiling, E. M. K. (1938) · JAMA · doi:10.1001/jama.1938.72790360005007 · Cited by 199
Minitablets: New Modality to Deliver Medicines to Preschool-Aged Children
Thomson, S. A., Tuleu, C., Wong, I. C. K., Keady, S., Pitt, K. G., & Sutcliffe, A. G. (2009) · Pediatrics · doi:10.1542/peds.2008-2059 · Cited by 193
Optimizing oral medications for children
Mennella, J. A., & Beauchamp, G. K. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.018 · Cited by 188
Drug metabolism and disposition in children
Strolin Benedetti, M., & Baltes, E. L. (2003) · Fundamental & Clinical Pharmacology · doi:10.1046/j.1472-8206.2003.00140.x · Cited by 182
“Inactive” Ingredients in Pharmaceutical Products: Update (Subject Review)
Committee on Drugs (1997) · Pediatrics · doi:10.1542/peds.99.2.268 · Cited by 162
Benedetti, M. S., Whomsley, R., & Baltes, E. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.3.447 · Cited by 155
Developing paediatric medicines: identifying the needs and recognizing the challenges
Ernest, T. B., Elder, D. P., Martini, L. G. A., Roberts, M., & Ford, J. L. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.8.0001 · Cited by 146
Challenges of developing palatable oral paediatric formulations
CRAM, A., Breitkreutz, J., Desset-Brèthes, S., Nunn, T., & Tuleu, C. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.09.015 · Cited by 143
Off-Label Prescribing to Children in the United States Outpatient Setting
Bazzano, A., Mangione-Smith, R. M., Schonlau, M., Suttorp, M. J., & Brook, R. H. (2009) · Academic Pediatrics · doi:10.1016/j.acap.2008.11.010 · Cited by 141
Abdulla, S., Sagara, I., Borrmann, S., D’Alessandro, U., González, R., Hamel, M. J., Ogutu, B. R., Mårtensson, A., Lyimo, J., Maiga, H., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61492-0 · Cited by 141
Extemporaneous drug formulations
Nahata, M. C., & Allen, L. V. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.020 · Cited by 129
Lack of appropriate formulations of medicines for children in the community
Schirm, E., Tobi, H., de Vries, T., Choonara, I., & den Berg, L. D. J.-V. (2003) · Acta Paediatrica · doi:10.1080/08035250310006728 · Cited by 127
Mason, J., Pirmohamed, M., & Nunn, T. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1097-1 · Cited by 124
Medicines for Children: A Matter of Taste
Davies, E. H., & Tuleu, C. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.06.030 · Cited by 119
Walsh, J., Bickmann, D., Breitkreutz, J., & Chariot-Goulet, M. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.048 · Cited by 114
Garvie, P. A., Lensing, S., & Rai, S. N. (2007) · PEDIATRICS · doi:10.1542/peds.2006-1488 · Cited by 99
Stimulation programs for pediatric drug research – do children really benefit?
Boots, I., Sukhai, R. N., Klein, R. H., Holl, R. A., Wit, J. M., Cohen, A. F., & Burggraaf, J. (2007) · European Journal of Pediatrics · doi:10.1007/s00431-006-0381-z · Cited by 93
Krishnan, V., Xu, X., Barwe, S. P., Yang, X., Czymmek, K. J., Waldman, S. A., Mason, R. W., Jia, X., & Rajasekaran, A. K. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300350e · Cited by 86
In vitro gastrointestinal model (TIM) with predictive power, even for infants and children?
Havenaar, R., Anneveld, B., Hanff, L. M., et al. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.07.053 · Cited by 85
Materials to Clinical Devices: Technologies for Remotely Triggered Drug Delivery
Timko, B. P., & Kohane, D. S. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.09.012 · Cited by 51
van Riet‐Nales, D. A., Schobben, A. F. A. M., Egberts, T. C. G., & Rademaker, C. M. A. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.05.005 · Cited by 44
Self-citationKayitare, E., Vervaet, C., Ntawukulilyayo, J. D., Seminega, B., Bortel, V., & Remon, J. P. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.11.005 · Cited by 43
Ethanol in liquid preparations intended for children
Pruitt, A., Anyan, W. R., Niebyl, J. R., et al. (1984) · Cited by 39
Giacoia, G. P., Taylor‐Zapata, P., & Zajicek, A. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.09.013 · Cited by 33
Assessing the palatability of medications in children
Matsui, D. M. (2007) · Paediatric and Perinatal Drug Therapy · doi:10.1185/146300907x178941 · Cited by 32
Trends in accessibility to medicines for children in New Zealand: 1998–2002
Chui, J., Tordoff, J. M., Kennedy, J., & Reith, D. M. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.02014.x · Cited by 26
Assessing taste without using humans: Rat brief access aversion model and electronic tongue
Clapham, D., Kirsanov, D. O., Legin, A. V., Rudnitskaya, A. M., & Saunders, K. A. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.05.056 · Cited by 24
Oral phenytoin in infancy: dose requirement, absorption, and elimination.
Albani, M., & Wernicke, I. (1983) · PubMed · Cited by 18
Bridging studies in support of oral pediatric formulation development
Ricci, B. M. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.07.074 · Cited by 18
Cited by
Lopez, F. L., Ernest, T. B., Tuleu, C., & Gul, M. O. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1060218 · Cited by 265
Rampedi, P. N., Ogunrombi, M. O., & Adeleke, O. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060712 · Cited by 15
Metadata
- Authors
- Ivanovska, V., Rademaker, C. M. A., van Dijk, L., & Mantel-Teeuwisse, A. K.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2014-08-01
- Volume
- 134
- Issue
- 2
- Pages
- 361-372
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2157788227
- Cited by
- 324
- References
- 44
- FWCI
- 18.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.